US 12,168,686 B2
Method of treating cancer using disulfide-linked trimeric OX40L
Peng Liang, Chengdu Sichuan (CN)
Assigned to Sichuan Clover Biopharmaceuticals, Inc., Chengdu (CN)
Filed by Sichuan Clover Biopharmaceuticals, Inc., Sichuan (CN)
Filed on Oct. 16, 2022, as Appl. No. 17/966,884.
Application 17/966,884 is a continuation of application No. 16/807,539, filed on Mar. 3, 2020, granted, now 11,472,873.
Application 16/807,539 is a continuation of application No. 16/803,126, filed on Feb. 27, 2020, granted, now 11,377,490.
Application 16/803,126 is a continuation in part of application No. 15/609,612, filed on May 31, 2017, granted, now 10,618,949.
Prior Publication US 2023/0272060 A1, Aug. 31, 2023
Int. Cl. A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 38/19 (2006.01); A61K 39/00 (2006.01); C07K 14/52 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01)
CPC C07K 16/241 (2013.01) [A61K 9/0019 (2013.01); A61K 38/191 (2013.01); A61K 39/4636 (2023.05); C07K 14/52 (2013.01); C07K 16/2827 (2013.01); C07K 16/2875 (2013.01); A61K 38/00 (2013.01); A61K 39/001129 (2018.08); C07K 2319/00 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A method for treating cancer in a mammal, comprising a step of administering to said mammal a therapeutically effective amount of a disulfide bond-linked trimeric OX40L fusion protein, wherein the disulfide bond-linked trimeric OX40L fusion protein comprises the amino acid sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 6.